Sumitomo Mitsui Trust Group Inc. Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Sumitomo Mitsui Trust Group Inc. lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 0.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 303,669 shares of the biopharmaceutical company's stock after acquiring an additional 1,053 shares during the period. Sumitomo Mitsui Trust Group Inc. owned approximately 0.28% of Regeneron Pharmaceuticals worth $192,596,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $25,000. Rakuten Securities Inc. boosted its stake in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares during the period. OFI Invest Asset Management bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $28,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares during the period. Finally, Avalon Trust Co bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $36,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN remained flat at $521.00 during midday trading on Friday. The stock had a trading volume of 1,607,735 shares, compared to its average volume of 899,578. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The company's 50 day simple moving average is $554.18 and its two-hundred day simple moving average is $631.95. The company has a market cap of $56.25 billion, a PE ratio of 13.26, a PEG ratio of 1.91 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. Regeneron Pharmaceuticals's revenue was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $9.55 EPS. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.68%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and dropped their price target for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. Bank of America dropped their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research note on Thursday, April 17th. Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. Finally, UBS Group dropped their price target on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating for the company in a research note on Thursday, June 5th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $822.58.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.